Collegium Pharmaceutical (COLL) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $80.2 million.
- Collegium Pharmaceutical's Cost of Revenue rose 2828.96% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.9 million, marking a year-over-year increase of 4359.88%. This contributed to the annual value of $254.1 million for FY2024, which is 561.39% up from last year.
- According to the latest figures from Q3 2025, Collegium Pharmaceutical's Cost of Revenue is $80.2 million, which was up 2828.96% from $79.6 million recorded in Q2 2025.
- Over the past 5 years, Collegium Pharmaceutical's Cost of Revenue peaked at $83.7 million during Q4 2024, and registered a low of $28.7 million during Q4 2021.
- Over the past 5 years, Collegium Pharmaceutical's median Cost of Revenue value was $61.7 million (recorded in 2023), while the average stood at $58.7 million.
- In the last 5 years, Collegium Pharmaceutical's Cost of Revenue soared by 17820.53% in 2022 and then tumbled by 3096.04% in 2023.
- Quarter analysis of 5 years shows Collegium Pharmaceutical's Cost of Revenue stood at $28.7 million in 2021, then surged by 178.21% to $79.8 million in 2022, then crashed by 30.96% to $55.1 million in 2023, then skyrocketed by 51.79% to $83.7 million in 2024, then dropped by 4.15% to $80.2 million in 2025.
- Its Cost of Revenue was $80.2 million in Q3 2025, compared to $79.6 million in Q2 2025 and $80.4 million in Q1 2025.